Global Batten Disease Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

Global Batten Disease Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • August 2019 •
  • 59 pages •
  • Report ID: 5811360 •
  • Format: PDF
High levels of pipeline activity are being observed in Batten Disease treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Abeona Therapeutics Inc, Amicus Therapeutics, Blue Turtle Bio Technologies Inc, Circumvent Pharmaceuticals Inc, Collaborations Pharmaceuticals Inc and others.

A Significant contribution to the Batten Disease pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Batten Disease pipeline included 13 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Batten Disease condition and increased access to investments is encouraging growth of Batten Disease drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Batten Disease drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Batten Disease therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Batten Disease pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Batten Disease. Further, orphan drug status, fast track designation, grants awarded and other special status for Batten Disease pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Batten Disease pipeline and formulate effective research and development strategies.

Research Methodology
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Batten Disease Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Batten Disease drugs
- Late phase: Phase 3 and in-approval Batten Disease drugs

Companies involved in the Pipeline-
- Company overview
- Snapshot
- Batten Disease therapeutic treatment activities

Details for each Batten Disease drug candidate-
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details

Other details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate

Recent Batten Disease therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news